DECISION AND ORDER
INTRODUCTION
Plaintiff Rochester Drug Co-operative, Inc. (“Plaintiff’) has sued Defendant Biog-en Idee U.S. Corporation (“Defendant”)
Plaintiffs Complaint against Defendant asserts five causes of action arising out of Defendant’s termination of its distribution contract'with Plaintiff: (1) violation of the Donnelly Act, N.Y. Gen. Bus. Law § 340; (2) injunctive relief under N.Y. CPLR 6301; (3) anticipatory breach of contract; (4) breach of the covenant of good faith and fair dealing; and (5) declaratory relief under N.Y. CPLR 3001. (Dkt. 1).
Defendant has moved.to dismiss the entire Complaint under Rule 12(b)(6) of the Federal Rules of Civil Procedure. (Dkt. 6). Plaintiff has moved for a preliminary injunction, restraining Defendant from taking any steps in furtherance of the termination decision. (Dkt. 9, 15). The Court held oral argument on September 15, 2015, and reserved decision.
The, Court is sensitive to the potential adverse impacts that Defendant’s termination decision may have on Defendant’s former regional wholesalers including Plaintiff, the local and independent pharmacies they service, and the pharmacies’ patients, particularly those living in rural areas. The indisputable trend in the pharmaceutical industry, as reflected in Defendant’s decision and similar decisions made by countless other pharmaceutical manufacturers, ’ is to distribute drugs through mammoth-sized wholesalers. As a result, the local community drug store, where prescriptions are filled while folks visit with their pharmacist and neighbors, appears to be fading from'our society, and their customers are increasingly being forced to obtain their pharmaceuticals through other means.
Nevertheless, the law permits corporations to make these types of distribution decisions without regard to societal impact, so long as they do not engage in an unlawful bilateral arrangement for anti-competitive purposes. Because Plaintiffs Complaint fails to plausibility allege that Defendant’s termination decision was the product of an unlawM reciprocal arrangement, "Defendant’s motion to dismiss (Dkt. 6) is granted and Plaintiffs Complaint (Dkt. 1) is dismissed in its entirety. Plaintiffs motion for' preliminary injunction (Dkt. 9) is denied.
I. The Parties
Plaintiff is a wholesale drug cooperative that buys and distributes a complete line of pharmaceuticals and home health supplies to community retail pharmacies, long-term care pharmacies, and home health care stores. (Dkt. 1, CompU 5). Plaintiffs customers are located primarily in New York, New Jersey, Pennsylvania, and Ohio, in both metropolitan and rural areas of those states. {Id. ¶ 6).
Defendant is a biotechnology corporation that develops, markets, and sells pharmaceutical products, including the drug Avonex. {Id. ¶ 7).
II. The Drug Avonex
Avonex treats “patients with relapsing forms of multiple sclerosis (‘MS’) to delay the progression of physical disability and reduce ‘flare ups’ of MS symptoms.” {Id. ¶ 10). Avonex is the only interferon beta on the market that is administered through intramuscular injection, as opposed to a subcutaneous injection. {Id. ¶ 41). Avonex needs to be administered only once a week. {Id.).
Avonex is sold in three formulations. The Avonex Pre-Filled Syringe is a conventional syringe. {Id. ¶ 10). The Avonex Powder Form is a lyophilized vial of powder that is manually mixed before injection. {Id.). The Avonex Pen is a prefilled needle that can be administered with a single click and “was designed to improve a patient’s ability to self-administer ’Avonex.” {Id. ¶ 13). According to Plaintiff, “[f]or many patients, Avonex is administered by licensed pharmacists in pharmacies.” {Id. ¶ 15).
III. The Big Three
Three wholesalers generate 85 to 90 percent of all revenues from drug distribution in the United States. {Id. ¶34). Those three wholesalers are Cardinal Health, McKesson Corporation, and AmerisourceBergen Corporation (commonly known as, and collectively referred to herein as, the “Big Three”). {Id.). They are the largest drug wholesalers in the nation. {Id.). The great majority of all pharmacies in the United States, including all of the large retail pharmacy chains, receive 'pharmaceuticals from the Big Three. {Id. ¶ 22).
The Big Three supply only to pharmácies that purchase a minimum volume amount of pharmaceuticals. {Id. ¶25). Many of the smaller pharmacy chains and independent pharmacies serviced by regional wholesalers like Plaintiff lack-.the volume requirements to purchase pharmaceuticals .from the Big Three. {Id. ¶¶ 24-25). ,
IY. The Wholesaler Distribution Agreement
On or about January 1, 2009; Plaintiff and Defendant entered into a Wholesaler Distribution Agreement (the “Distribution Agreement”), which was supplemented by Defendant’s letter dated March 14, 2012, whereby Plaintiff was appointed as an authorized wholesaler of Defendant’s Avonex products. {Id. ¶¶ 17-21). Plaintiff has performed under the Distribution Agreement for over six years. {Id. ¶ 19).
V. Termination of the Distribution Agreement
By letter dated March 23, 2015, Defendant informed Plaintiff that it was terminating the Distribution Agreement, effective June 30, -2015 (the “Termination Letter”). ■ {Id. ¶29). The' Termination Letter stated that> as of July 1, 2015, Avonex would be available for purchase only from the Big Three. {Id. ¶33). The Termination Letter also stated that Plaintiff could continue to sell Avonex out of its existing inventory for a period not to exceed 90 days from the date of termination. {Id. ¶ 54; Dkt. 6-4 at 2).
Plaintiffs allegations of unlawful arrangement • are located in paragraphs 52 through 56 of the Complaint. In paragraphs 52 and 53, Plaintiff. alleges that Defendant’s Termination Letter demonstrates that-Defendant has entered into an agreement or arrangement with the Big Three to exclude all other wholesalers, including Plaintiff,.from the relevant market, which is alleged to be “Avonex in all strengths and forms” in the United States. (Dkt. 1, Compl. ¶¶ 41, 52-53). In paragraph 54, Plaintiff alleges that-Defendant’s 90-day limit on the time by which Plaintiff must stop selling Avonex was instituted to protect the Big Three’s sales and profits. (Id ¶ 54)..
In paragraph 55, Plaintiff alleges that Defendant’s decision to terminate the regional wholesalers was against Defendant’s economic interests, because pharmacies in mostly rural areas will no longer be able to obtain Avonex, which will cause Defendant to lose sales. (Id ¶ 55). Elsewhere in the Complaint, Plaintiff asserts that these small pharmacies might not be able to obtain Avonex due to one or more Of the following reasons: (1) the inability to meet the volume requirements of the Big Three; (2) the inability to pay the fees of the Big Three on a profitable basis; and/or (3) the inability to obtain needed services from the Big Three. (Id. '¶¶ 25-26). *
In paragraph 56, Plaintiff alleges that the-unlawful arrangement will restrict output and increase the .cost of Avonex and, in some areas, access to Avonex, will be eliminated. (Id. ¶ 56). Elsewhere in the Complaint, Plaintiff adds that the purpose of Defendant’s actions in reducing the output of-Avonex is to “increas[e] already supra-competitive margins for its Avonex monopoly.” (Id. ¶ 68).
VII. Procedural History
Plaintiff commenced this action in state court on June 25, 2015. (Dkt. 1, Notice of Removal 1). Defendant timely removed the action to this Court on June 26, 2015, based upon diversity jurisdiction. (Id. ¶ 6): On July-17, 2015, Defendant filed a motion to dismiss the Complaint under Rule 12(b)(6) of the Federal Rules of Civil Procedure. (Dkt. 6). On August 7, 2015, Plaintiff filed its original motion for a preliminary injunction (Dkt. 9), and, on August 10, 2015, Plaintiff filed an amended motion for preliminary- injunction (Dkt. 15). The parties filed their response papers (Dkt. 18, 20) and reply papers (Dkt. 21, 23), as well as supporting declarations and exhibits. Oral argument was held on September 15, 2015, and the Court reserved decision.
DISCUSSION
I. Legal Standard
Rule 8 of the Federal Rules of Civil Procedure provides that a complaint must contain “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed.R.Civ.P. 8(a)(2). The factual allegations in a complaint “must be enough to raise a right to relief above the spéculative level....” Bell Atl. Corp. v. Twombly,
“To survive a motion-to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to
The plausibility standard “asks for more than a sheer possibility’,’ that a defendant has acted unlawfully. Id. “Where a complaint pleads facts that are ‘merely consistent with’ a defendant’s liability, it ‘stops short of the line between possibility and plausibility of ‘entitlement to relief.’ ’ ” Id. (quoting Twombly,
“[T]o be viable, a complaint must contain ‘enough factual matter (taken as true) to suggest that an agreement [to engage in anticompetitive conduct] was made.’ ” In re Elevator Antitrust Litig.,
II. Plaintiffs Donnelly Act Claim
Plaintiff alleges that Defendant’s decision to discontinue its distributorship
A. The Donnelly Act
Plaintiff appears to suggest that “a unilateral exertion of power” is sufficient to fall within the scope of the Donnelly Act. (Dkt. 18 at 18). The Court cannot agree. The United States Supreme Court has long held that “[a] manufacturer .., generally has a right to ... refuse to deal[ ] with whomever it likes, as long as it does so independently.” Monsanto Co. v. Spray-Rite Serv. Corp.,
The Donnelly Act does not proscribe unilateral action, but only a “contract, agreement, arrangement or combination” in restraint of trade. N.Y. Gen. Bus. Law § 340. In State v. Mobil Oil Corp.,
In making the ease that unilateral conduct suffices under the statute, Plaintiff heavily relies upon People v. B.P. Oil Corp.,
The holding in B.P. Oil, which appears to be that a unilateral exertion of power may fall within the Donnelly Act, does not reflect the current state of the law in New York, and, therefore, the Court does not accord it any precedential weight. Mobil Oil flatly rejected the idea that a unilateral exertion of power can state a claim under the Donnelly Act when it stated that “a one-sided practice ... is outside the scope of the statute.”
Although a unilateral exertion of power does not fall within the Donnelly Act, Plaintiff is correct in arguing that the inclusion of the word “arrangement” in the Donnelly Act makes the scope of the antitrust statute broader than § 1 of the Sherman Act.
[Ujnder the familiar canon of statutory construction, noscitur a sociis, the term, “arrangement”, takes on a connotation similar to that of the other terms with which it is found in company, and thus must be interpreted as contemplating a reciprocal relationship of commitment between two or moré legal or economic entities similar to but not embraced within the more exacting terms, “contract”, “combination” or “conspiracy”.
Mobil Oil,
Thus, to fall within the ambit of the Donnelly Act, a jilted distributor may not rely only upon a manufacturer’s unilateral exertion of power to terminate a distributorship. On the other hand, the jilted distributor need not allege a formal agreement or conspiracy, so long as the arrangement to restrain trade involves a “reciprocal relationship of commitment” between two or more entities.
To survive Defendant’s motion to dismiss, Plaintiff must allege facts that make it plausible that Defendant’s termination decision was the product of a reciprocal' arrangement with the Big Three; unilateral action that might have inured to the benefit of the Big Three is not enough to maintain a Donnelly Act claim. Yankees Entm’t & Sports Network, LLC v. Cablevision Sys. Corp.,
■ In this case, Plaintiffs Complaint does not set forth any factual matter concerning the behavior of the distributors alleged to be co-participants in the unlawful arrangement with Defendant. The Complaint is completely devoid of any discussions', interactions, or activities of the Big Three in connection with the termination of Plaintiffs distributorship. The only facts alleged in the Complaint relate to Defendant’s action in notifying Plaintiff of the termination of Plaintiffs distributorship. In the absence of any facts concerning the actions of the Big Three, the Court is hard-pressed to infer a reciprocal relationship of commitment' between Defendant and any of the Big Three.
Plaintiff attempts to create an inference of an unlawful arrangement by pointing to the Big Three’s continued distribution of Defendant’s Avonex products after the termination of the regional distributorships and their financial gains from Defendant’s distribution change. Plaintiff further asserts that Defendant’s distribution plan is against Defendant’s own economic interest and gives a list of theoreticál discussions which “must have” occurred between Defendant and the Big Three to make the plan an economically sensible one for Defendant. None of these allegations, whicli are discussed in turn below, raises a plausible suggestion of a reciprocal arrangement of commitment as required under the Donnelly Act.
1. Continued Distribution
The law is well settled that a conclusory allegation of an unlawful arrangement is insufficient to state a claim for relief under the Donnelly Act. See Mini-Frame Ltd. v. Microsoft Corp., No. 11 CIV. 7419 RJS,
In- this case, Plaintiff makes the following allegation of an unlawful arrangement in paragraphs 52 and 53 of the Complaint:
[Defendant’s] Termination Letter demonstrates that [Defendant] has entered into an agreement or arrangement with the Three Wholesaler Co-Conspirators to exclude all other wholesalers, including RDC, from the relevant market. The Termination Letter states as follows: “[a]s of July 1, 2015, Avonex will only be available to purchase from AmerisourceBergen, McKesson Corporation and Cardinal Health.” Biogen ánd the Three Wholesaler Co-Conspirators have agreed that all other wholesalers, including RDC, would be terminated as of July 1,2015.
(Dkt. 1, Compl. ¶¶ 52-53). Contrary to Plaintiffs argument otherwise, the reference to the Big Three in the Termination Letter does not raise a plausible suggestion of an unlawful arrangement. Defendant’s decision to streamline its distribution strategy by terminating Plaintiffs distributorship and other regional distributorships was not dependent upon the approval or involvement' of any other distributor, including any of the Big Three. Under the terms of the parties’ Distribution Agreement, Defendant could unilaterally terminate Pláintiffs distributorship with or without cause upon notice. The Distribution Agreement specifically provides that ’ “[Defendant] may terminate this Agreement, with or without cause, upon not less than ninety (90) days prior written notice to [Plaintiff].” (Dkt. 6-3 at 18).
2. Financial Gain
Plaintiff asserts that an unlawful arrangement can be reasonably inferred from the mere assertion that the Big Three “have much to gain” from Defendant’s new distribution strategy. (Dkt. 18 at 12). In paragraph 54 of the Complaint, Plaintiff alleges that an inference of an unlawful arrangement follows from Defendant’s prohibition of sales of Avonex by regional distributors after a 90-day limitation period because the prohibition/limitation allegedly protects the Big Three’s sales and profits. (Dkt. 1, ■ Compl. ¶ 54).
Unilateral action is insufficient to support a claimed violation of the Donnelly Act even when the “unilateral action ... could have the effect of giving one [distributor] an advantage over another.” Hall Heating Co. v. N.Y. State Elec. & Gas Corp.,
3. Contrary to Defendant’s Economic Interest
Plaintiffs antitrust conspiracy theory rests almost entirely on the allegation that Defendant’s abandonment of the regional wholesalers was against Defendant’s own economic interests. Based upon the theory that Defendant’s elimination of regional wholesalers will cause Defendant to lose sales, Plaintiff contends that it has raised a plausible suggestion of conspiracy or unlawful arrangement. In
Plaintiff explains that “mom and pop” pharmacies will likely be unable to obtain Avonex due to one or more of the following reasons: (1) the inability to meet the volume requirements of the Big Three; (2) the inability to pay the fees of the Big Three on a profitable basis; and/or (3) the inability to obtain services from the Big Three. (Dkt. 1, Compl. ¶¶ 25-26). Plaintiff contends that as a result of the elimination of the regional wholesalers and the concomitant inability of the small pharmacies to carry Avonex, patients, mostly in rural areas, will have their access to Avonex restricted or completely eliminated. However, there are numerous flaws in Plaintiffs theory.
First, and perhaps most significantly, Defendant’s distribution plan is not featured in the Complaint as an irrational decision that goes against the sound practices of other manufacturers in the pharmaceutical industry. On the contrary, the Complaint tells a very different 'story. As alleged in the Complaint, the distributors that Defendant chose to distribute Avonex are the three largest wholesalers in the industry. The Big Three generate an astounding 85 to 90 percent of all revenues from drug distribution in the United States. (Id. ¶ 34). The great majority of all pharmacies in the United States, including all of the large retail pharmacy chains, receive pharmaceuticals from these three -wholesalers. (Id. ¶ 22). Hence, the allegations of the Complaint' themselves suggest that Defendant’s decision to distribute exclusively through the Big Three was not the poor1 business decision, that Plaintiff argues that it was.
Second, even assuming arguendo that Defendant might experience a loss of revenue from the small, mostly rural, pharmacies,' there is no reason amplified in the Complaint as to why Defendant could not Recapture those sales through other distribution outlets. The allegations of the Complaint, again, do just the opposite. The allegations suggest that Avonex patients would find alternative means to obtain the drug for the treatment of their MS disease even if Avonex is unavailable at their local pharmacy.
For one, patients could “obtain the Avonex treatment that they require from a pharmacy supplied by the [Big Three].” (Id. ¶28). While Plaintiff alleges that some patients, particularly those that reside in rural areas, would have to travel “great distances” (id. ¶ 28), the allegations suggest that patients of Avonex would find a feasible way to do so.- As alleged in the Complaint, Avonex has ño' comparable substitutes. (Id. ¶¶ 41-50). No other treatment for MS, including several drugs available on the market, can be effectively substituted for Avonex due to the allegedly unique characteristics of Avonex. (Id.)
Another alternative .distribution outlet available to Avonex patients is evident from the allegations in the Complaint, namely, that Avonex- treats a long-term condition and is capable of being self-administered. Avonex treats “patients with
Third, even assuming that Defendant might see some residual loss from reluctant patients who decide not to purchase Avonex through alternative means, the Complaint does not attempt to quantify the extent of that loss. If anything, the Complaint (and in particular the allegations pertaining to the volume of business generated by the regional distributors) suggest that any such loss would be miniscule, at least from Defendant’s perspective. The Complaint is riddled with allegations comparing the rather small volume of sales handled by the regional distributors to the substantial volume of sales generated by the Big Three. (Dkt. 1, Compl. ¶ 22 (“The [Big Three] distribute ... Avonex, to a great majority of all pharmacies in the United States,-including all the- large retail pharmacy chains that service larger urban and suburban areas.”); id. ¶23 (“[T]he [Big Three] focus their attention on Idrger pharmacies that have substantial volume requirements.”); id. ¶ 24 (“Regional wholesalers, such as RDC, service smaller pharmacy chains and independent pharmacies, including those in urban, suburban, and ■rural areas of New York and other surrounding states. Many of these pharmacies lack the volume requirements upon which the [Big Three] insist before they will agree to supply a pharmacy.”)). The Court cannot reasonably infer that Defendant’s distribution plan negatively impacts Defendant’s own economic interests without any quantification of the extent of Defendant’s supposed losses.
Fourth, and finally, Plaintiffs economic theory wholly ignores that there may be economic benefits and savings associated with using a national distribution plan.
A similarly conclusory allegation of an unlawful arrangement led a district’ court in this circuit to dismiss a Donnelly Act claim in Worldhomecenter.com, Inc. n KWC Am., Inc., No. 10 CIV. 7781 NRB, 2011WL 4352390, at *6 (S.D.N.Y. Sept. 15, 2011), which, although not cited by the parties, is instructive. There, the plaintiff brought suit against a manufacturer,claiming, inter alia, that an. advertising policy was an unlawful restraint in violation of the Donnelly Act. Id. at *1, *6. The plaintiff alleged that the existence of agreements between the-manufacturer and other distributors could be inferred because “without such agreements, the [policy] would not be in [the manufacturer’s] own best interests.” Id. at *6. The plaintiff claimed that the policy represented a quid pro quo in that-the policy protected the remaining dealers from competition in exchange for the dealers’ agreement to continue distributing the manufacturers’ products. - Id. The court disagreed, holding that the plaintiff had failed-to allege sufficient facts from which joint action could be inferred. The court reasoned that “specific factual allegations of such an arrangement [wer]e absent from the complaint.” Id. at *6-7. In addition, the court, found that the allegations of the complaint did not adequately raise an inference that the policy was actually against the manufacturer’s interests. Id. at *7. In that regard, the court gave some possible reasonable justifications that the defendant may have had for imposing the policy, but noted that the defendant was not obligated to offer any kind of a detailed explanation of its reasons. Id, at *6. Further, the court cited .Colgate and the right of a manufacturer freely to exercise its own independent discretion as to the parties with whom it deals. Id.
As in Worldhomecentef.com, this Court cannot infer an arrangement between Defendant and the Big Three based only upon Plaintiffs bald contention that Defendant’s adoption of its new distribution plan would be harmful to Defendant’s own economic interests. Given.the realities of the pharmaceutical industry and common economic experience, there is insufficient factual information in the Complaint to support-the sweeping allegation that Defendant adopted a distribution plan against its very own economic interests. Defendant may have reasonable justifications for the distribution plan, such as the offsetting cost savings and efficiencies offered by national distribution. Further, Plaintiff has not alleged adequate factual allegations from which an arrangement to restrain competition could be inferred. Absent such an arrangement, Defendant is protected under the cloak of the Colgate doctrine and can freely refuse to sell its products to a particular distributor or set of distributors.
Given the conclusory allegations of the Complaint, the Court is unwilling to make the inferential leap that Defendant and the Big Three formed an arrangement to restrain competition. As stated in Worldhomecenter.com, “that the [distribution plan]
4. Alleged Reassurances
Plaintiff contends that it is implausible that Defendant would have made a decision to terminate Plaintiffs distributorships without first consulting the Big Three. (Dkt. 18 at 10-12). Building upon its argument that the distribution plan is against Defendant’s economic interests, Plaintiff contends that Defendant -'“must have” obtained reassurances from the Big Three that they would be able to sell to the small and independent pharmacies. The Court has already rejected Plaintiffs conclusory allegation that Defendant’s new distribution plan was against Defendant’s economic interests in light of the allegations of the Complaint itself. Ergo, Plaintiffs related argument that Defendant “must have” made an arrangement with the Big Three to make Defendant’s plan a financially viable one is equally unsound. While the Court could stop its analysis there, the Court concludes that Plaintiffs contention that Defendant had pre-termination discussions with the Big Three does not, in any event, allege an unlawful arrangement.
Plaintiff surmises'. that Defendant and the three distributors entered into one of the following three possible “arrangements” prior to the termination decision:
• [A]n arrangement between Biogen and the Three Wholesalers that would enable the latter to re-sell Avonex to at ' least some other regional distributors.12
* [A]n arrangement between Biogen and the Three Wholesalers that the latter would now sell Avonex to large chain pharmacies for resale to independent pharmacies.
• [A]n arrangement ■ that the Three Wholesalers would alter their volume requirements so that .independent pharmacies previously served by regional wholesalers like RDC could now purchase from the Three Wholesalers.
(Dkt. 18 at ll).
Although Plaintiff contends ‘that Defendant and the Big Three entered into oné of these three arrangements, Plaintiff admits that it is “not privy to the exact nature” of the understanding. (Dkt. 18 at 11). More to the point, Plaintiff does not allege any factual matter whatsoever to support Plaintiffs argument that any of these theoretical possibilities actually occurred. As
That Defendant and the Big Three may have exchanged information on prospective distribution strategy does not mean that Defendant was not making an independent termination decision regarding Plaintiffs distributorship. See also Monsanto Co. v. Spray-Rite Serv. Corp.,
■ The Court rejects Plaintiffs argument that several New York cases support its contention that the allegations in the Complaint constitute an “arrangement” under the Donnelly Act, including Eagle Spring Water Co. v. Webb & Knapp, Inc.,
In Eagle Spring Water,
A supplier’s use of pressure and financial inducements to ’'exclude a rival was also the basis for the court’s finding of a Donnelly Act violation in Alexander’s Dep’t Stores,
A manufacturer has a right to pick his own customers and refuse to sell to a particular customer provided that such refusal is not the result of a combination with others to destroy competition so far as the whole product of important manufacturers is concerned. We think that section 340 was intended to prevent the practice that Ohrbach here engaged in, whereby a larger competitor using the pressure of superior buying power seeks to eliminate one by one smaller competitors by seeking arrangements with manufacturers, such as the one here in question, to refuse to sell to competitors and cut off their supply, though they have been buying the products and competing in them for years.
Id. at 539,
In conclusion, due' to the absence of allegations suggestive of an unlawful' reciprocal relationship of commitment, the Court concludes that the allegations of the Complaint do not' state a claim to relief that is plausiblé on its face.
III. Remaining Claims
As Plaintiff acknowledged at oral argument, the remaining claims in the Complaint are premised on Plaintiffs assertion that Defendant’s conduct violated the.Donnelly Act and/or was the result of a bad-faith arrangement with the Big Three. Plaintiff asserts the following additional claims: injunctive relief under N.Y. CPLR 6301 (second cause of action); anticipatory breach of contract based upon Defendant’s anticompetitive arrangement (third cause of action); breach of the covenant of good faith and fair dealing (fourth cause of action); and declaratory relief under N.Y. CPLR 3001 that Defendant violated the Donnelly Act (fifth cause of action). Because Plaintiff has not adequately pled a claim for. relief under the Donnelly Act or any other bad-faith arrangement with the Big Three, the remaining claims must be dismissed.
CONCLUSION
For the foregoing reasons, Defendant’s motion to dismiss (Dkt. 6) is granted, and Plaintiffs Complaint (Dkt. 1) against Defendant js dismissed with prejudice. Plaintiffs motions for preliminary injunction (Dkt. 9,15) are denied. ,
SO ORDERED.
Notes
. As of March 27, 2015, Defendant now operates under the corporate name Biogen Inc. (Dkt. 6-1 at 6 & n, 1).
. In its papers submitted to the Court, Defendant argued that the Complaint in this case failed to meet the pleading requirements' of Rule 8(a) due to the absence of any allegations identifying the "specific time, place, or person” involved in the alleged arrangement. (Dkt. 6-1 at 14 (quoting Twombly,
Hence, under Twombly, while a Sherman Act § 1 complaint premised on direct evidence of an agreement requires "time, place, or person” allegations regarding the claimed illegal agreement, complaints premised on circumstantial evidence, which are the lion’s share of the pleadings in the antitrust arena, do not require such factual matter. See Stan v. Sony BMG Music Entm't,
. "A party asserting a violation of the Donnelly Act must (1) identify the relevant product market, (2) describe the nature and effects of the purported conspiracy, (3) allege how the economic impact of that conspiracy is to restrain trade in the market in question, and (4) show a conspiracy or reciprocal relationship between two or more entities.” Yankees Entm’t & Sports Network, LLC v. Cablevision Sys. Corp.,
. Under the Sherman Act, "[e]very contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal.” 15 U.S.C. § 1. The Donnelly Act is generally patterned after the Sherman Act and is otherwise construed in light of federal precedent. Great Atl. & Pac. Tea Co. v. Town of E. Hampton,
. Contrary to Defendant’s apparent suggestion otherwise (Dkt. 6-1 at 11-12), an allegation that Defendant performed overt acts in furtherance of the alleged arrangement is not required to allege .a.Donnelly Act claim. See United States v. Socony-Vacuum Oil Co.,
. Defendant's suggestion that Plaintiff must plead conspiratorial "communications” to state'a plausible claim for relief (Dkt, 6-1 at 13) is somewhat imprecise. Although the Complaint must allege some facts about the behavior (which might include communications) of the participants to make it plausible that an unlawful arrangement was made, Defendant has cited no case that stands for the proposition that meetings and communications are required to state a Donnelly Act claim.
. At oral argument, Plaintiff conceded that the allegations of the Complaint purport to allege only a vertical conspiracy between Defendant and one or more of the Big Three, not a hub-and-spokes conspiracy also involving horizontal arrangements among -the Big Three, as hinted by Plaintiff in its filings with the Court. (Dkt. 11 at 18 n. 3.),
. Neither the Distribution Agreement nor the Termination Letter was attached to Plaintiff’s Complaint; instead, Defendant submitted the documents in support of Defendant’s Motion to Dismiss. (Dkt. 6-3, 6-4). Subsequently, Plaintiff attached the Distribution Agreement and the Termination Letter in support of its motion for a preliminary injunction. (Dkt. 10-1, 10-3). ■ Because the Distribution Agreement and the Termination Letter are integral to the Complaint, the Court may take the documents into consideration in deciding Defendant’s motion to dismiss without converting the motion into a motion for summary judgment. Chambers v. Time Warner, Inc.,
. While the Complaint alleges that "[flor máhy patients, Avonex is administered’by licensed pharmacists in pharmacies” (Dkt. 1, Compl. ¶ 15), that does not mean that the drug cannot be administered by a non-medi- ' cal person,
. Upon its initial review of the Complaint, the Court was struck by the lack of quantification and absence of any specification concerning Plaintiff’s own purchases and sales of Avonex. In the Court’s view, the reason that this information was absent from the Complaint was revealed by the information contained in Declaration of Kristi Paquette, filed by Defendant in opposition to. Plaintiffs motion for preliminary injunction. According to Ms, Paquette, in 2014, Plaintiff purchased approximately 424'units of Avonex, which represents less than 0.1% (one-tenth of one percent) of Avonex sales last year. (Dkt. 20-1 at ¶ 10). Plaintiff does not dispute the accuracy of this information. While the Court does not consider Ms. Paquette’s Declaration for purposes of deciding Defendant’s motion to dismiss, and instead bases its decision on -the four corners of the Complaint, the Court does agree with defense counsel’s contention made at oral argument that this information is at least relevant for purposes of concluding that any dismissal must be with prejudice. In other words, Plaintiff is unable to point to any additional facts not contained in the Complaint which would cure the failure to allege an unlawful reciprocal arrangement, and indeed, the facts submitted by Defendant suggest the exact opposite.
.Apart from the insufficiency of the allegations of Plaintiff's Complaint, the Court questions whether joint action can be inferred from the mere allegation that a plan is against a defendant’s self-interest. A bare allegation that a corporate policy is against a single corporation's economic interest does not imply joint action in any way. If alleging that a business policy was contrary to a corporation’s interests was enough alone to plead an antitrust conspiracy, a host of unilateral business decisions would be caught within the antitrust net. In- the absence of factual allegations that raise a suggestion of bilateral action, Defendant’s standalone disinterest in sales of Avonex to rural patients could be justified by any number of reasons, no one of which is made more plausible than the next by the allegations of the Complaint.
. While all of these hypothetical are discussed in Plaintiffs papers in opposition to Defendant's motion to dismiss (Dkt. 18 at 11), it appears that only the first hypothetical arrangement is alleged in the Complaint (Dkt. 1, Compl. ¶ 66).
. As Plaintiff’s list of theoretical possibilities grows, Plaintiff’s assertion that Defendant "must have” engaged in discussions with the Big Three prior to terminating Plaintiff’s distributorship becomes more attenuated. The more possibilities available to Plaintiff, the less likely pre-termination discussions were necessary, even under Plaintiff's conspiracy theory.
. Although not dispositive, the Court questions whether the Big Three would have been in a position to provide reassurances about the prospective purchase/sale transactions of third-party entities, like the regional wholesalers and the small pharmacies. In other words, even if the Big Three had agreed to lower their volume requirements or sell directly to regional wholesalers, the allegations of the Complaint indicate that there is some question as to whether these third parties would have had any-financial incentive to purchase from the Big Three. As Plaintiff alleges, if Plaintiff and/or its pharmacy customers purchased from the Big Three, they would “be forced to sell Avonex at a loss due to the thin wholesale margins on drug sales." (Dkt. 1, Compl. ¶ 65).
. In arguing for a broad reading of the Donnelly Act, Plaintiff cites Eagle Spring Water,
. Because the Court concludes that Plaintiff has not alleged an unlawful arrangement that violates the Donnelly Act, the Court need not consider the questions of whether Plaintiff has successfully alleged a single-brand market or ánti-competitive effects.
